Can digital tools really change patient behavior?

New research calls into question the behavioral effects of some digital health tools.

New tactics change clinical trial awareness game

New tactics change clinical trial awareness game

Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.

Sandoz lines up potential third-to-market Humira copy

Sandoz lines up potential third-to-market Humira copy

Although if approved, it's not likely to launch in the U.S. for quite some time.

Infographic | Docs, payers need pharma to step up

Infographic | Docs, payers need pharma to step up

For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.

OPEN LENS

Interview | Patrick Richard, Syneos Health Communications

How can pharma brands actionize the data they are collecting? Larry Dobrow, MM&M senior editor, and Patrick Richard, EVP and managing director, data sciences, Syneos Health, weigh in on leveraging data and analytics in this video, sponsored by Syneos.

YouTube announces measures to earn back trust from advertisers and agencies

YouTube announces measures to earn back trust from advertisers and agencies

In an effort to assure advertisers and agencies on brand safety, Google has announced two new requirements for video creators that intend to join the YouTube Partner Program.

Five things for pharma marketers to know: Wednesday, January 17, 2018

Five things for pharma marketers to know: Wednesday, January 17, 2018

Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer

McCann Health promotes Marcus Sigurdsson to global chief digital officer

McCann Health promotes Marcus Sigurdsson to global chief digital officer

Sigurdsson is charged with leading the agency's digital offering to meet growing client demand.

Five things for pharma marketers to know: Tuesday, January 16, 2018

Five things for pharma marketers to know: Tuesday, January 16, 2018

Merck's Keytruda combo therapy succeeds in Phase-III lung cancer trial; FDA launches pilot to address trial transparency; Spark's Luxturna overpriced, ICER says

What Facebook's news feed changes mean for brands and publishers

What Facebook's news feed changes mean for brands and publishers

Facebook's decision to reprioritise its news feed to favour "social interactions" over other forms of content may please its users but will be challenging for brands.

Five things for pharma marketers to know: Friday, January 12, 2018

Five things for pharma marketers to know: Friday, January 12, 2018

Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds

Stagwell's Penn says digital marketing agencies are 'undervalued' as he eyes more M&A

Stagwell's Penn says digital marketing agencies are 'undervalued' as he eyes more M&A

The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.

NORML balances federal, local action after Cole memo reversal

NORML balances federal, local action after Cole memo reversal

Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.

Day 3 at JP Morgan '18: More data, more questions

Day 3 at JP Morgan '18: More data, more questions

Collecting and analyzing data is a contentious question. High-profile data mavens offered some possible answers yesterday at the JP Morgan Healthcare Conference.

Five things for pharma marketers to know: Thursday, January 11, 2018

Five things for pharma marketers to know: Thursday, January 11, 2018

Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations

Day 2 at JP Morgan '18: Pharma's need for more diversity and data sharing grab the spotlight

Day 2 at JP Morgan '18: Pharma's need for more diversity and data sharing grab the spotlight

A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.

Five things for pharma marketers to know: Wednesday, January 10, 2018

Five things for pharma marketers to know: Wednesday, January 10, 2018

Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict

No Google, no problem: Pharma partners with China's tech giants

No Google, no problem: Pharma partners with China's tech giants

In the absence of behemoths such as Facebook and Twitter, pharma is partnering with China's tech giants to snare a slice of a more than $100 billion market

Day 1 at JP Morgan '18: Easier access to cash spells more M&A, say pharma CEOs

Day 1 at JP Morgan '18: Easier access to cash spells more M&A, say pharma CEOs

How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018